ASCO 2023 | Precision medicine for metastatic triple-negative breast cancer

So it has been a very important challenge in in breast oncology research to find innovative, targeted therapies and personalized therapies for patients with metastatic triple negative breast cancer. We already know that triple negative breast cancer is indeed a heterogeneous group of disease, but so far the treatment options that we have for personalized therapy are very, very limited. So it’s very important that we try to find these types of innovative approaches that in which we can select patients based on a biomarker and then use this biomarker as a personalized treatment approach. This type of treatment that we are trying to explore in the subsequent study has already been very successfully explored in patients with with prostate cancer. So we already know that it’s as a strategy, it’s something that can help some patients, but we don’t know exactly if this same strategy will apply for for patients with breast cancer. So that’s what we’re trying to explore as next steps in this study.